Lurasidone 20 mg daily + Lurasidone + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Lurasidone 20 mg daily + Lurasidone + Placebo
Lurasidone 20 mg daily + Lurasidone + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Autism. The current trial status is completed. This product is registered under clinical trial identifier NCT01911442. Target conditions include Autism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01911442 | Phase 3 | Completed |
Competing Products
20 competing products in Autism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ketamine + Placebo | Roivant Sciences | Phase 1 | 30 |
| Cord Tissue Mesenchymal Stromal Cells | Cryo-Cell | Phase 2 | 44 |
| Suramin Sodium | PaxMedica | Phase 2 | 44 |
| NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose group | Shionogi | Pre-clinical | 23 |
| Cariprazine + Placebo | AbbVie | Phase 3 | 77 |
| Cariprazine | AbbVie | Phase 1 | 33 |
| Omalizumab Injection [Xolair] | Novartis | Phase 1 | 33 |
| RO7017773 | Roche | Phase 1 | 33 |
| Placebo + RO7017773 | Roche | Phase 2 | 52 |
| Balovaptan | Roche | Phase 1 | 33 |
| Balovaptan | Roche | Phase 1 | 33 |
| Balovaptan + Esomeprazole | Roche | Phase 1 | 33 |
| Placebo + RG7314 | Roche | Phase 2 | 52 |
| Placebo + RO5285119 | Roche | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 3 | 77 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole | Bristol Myers Squibb | Phase 2 | 51 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |